Skip to content Skip to footer

Days After Hopeful Pfizer Vaccine News, 82% of Doses Bought by Richest Nations

Mass purchases of the vaccine by the richest countries have left more than 85% of the global population without access.

A sign for Pfizer is seen outside the Pfizer headquarters on November 9, 2020, in New York City.

Campaigners in the United Kingdom on Wednesday warned that just two days after pharmaceutical giant Pfizer shared positive early results of its coronavirus vaccine trial, mass purchases of the vaccine by the world’s richest countries have left more than 85% of the global population — namely, the world’s poorest — without any way to access it.

Pfizer says it can produce 1.35 billion doses of the vaccine, which was shown according to Pfizer’s first formal review to be 90% effective at preventing coronavirus infection in patients who have never had the virus, by the end of 2021. More than one billion of those doses — 82% of the supply — have already been purchased by wealthy countries.

The U.S. has purchased 100 million doses with an option to buy 500 million, enough to potentially immunize its entire population against the coronavirus with hundreds of millions of doses left over. Since Monday Pfizer has also sold 40 million doses to the U.K. and 200 million doses to the E.U., with an option to buy 100 million more.

In a statement, the British campaign group Global Justice Now noted that Pfizer’s partner in the development of the vaccine, German manufacturer BioNTech, has received financing of €375 million ($441 million) from the German government and €100 million ($117 million) from the European Investment Bank.

“Pfizer claims not to have had any state support, but the advance purchase of a billion doses of an unproven drug, not to mention the tax breaks and direct public funding of Pfizer’s partner suggests their claim is misleading at best,” said Global Justice Now director Nick Dearden. “Unless we break the stranglehold of these massive corporations over our medicines, the injustice will continue.”

Global Justice Now noted that Pfizer is likely to give some doses to developing countries through the World Health Organization’s Covid-19 Vaccines Global Access Facility (COVAX). However, those doses are expected to make up a small fraction of those produced by Pfizer, leaving billions of people without access to the vaccine.

COVAX has been undermined by the refusal of some wealthy countries, including the U.S., to take part in the global effort to ensure vaccine access, and now by mass purchases by some of those same countries.

“You couldn’t get a clearer example of how unequal the pharmaceutical system is — some make billions of pounds, while many others die because they cannot afford treatments or there are no more left for them to buy,” Dearden said. “It’s got to change.”

Global Justice Now repeated its call from earlier this week for the suspension of global patent rules to make it possible for poor countries to develop generic versions of Pfizer’s vaccine. South Africa and India last month proposed that the World Trade Organization suspend the rules on intellectual property for vaccines and treatments related to Covid-19.

“It is imperative that we end the vaccine nationalism and that sufficient supply is made available to all, on a fair basis, as a matter of urgency,” said Dearden. “That can be helped by supporting governments like South Africa and India who are trying to suspend intellectual property rules at the WTO during this global emergency.”

​​Not everyone can pay for the news. But if you can, we need your support.

Truthout is widely read among people with lower ­incomes and among young people who are mired in debt. Our site is read at public libraries, among people without internet access of their own. People print out our articles and send them to family members in prison — we receive letters from behind bars regularly thanking us for our coverage. Our stories are emailed and shared around communities, sparking grassroots mobilization.

We’re committed to keeping all Truthout articles free and available to the public. But in order to do that, we need those who can afford to contribute to our work to do so.

We’ll never require you to give, but we can ask you from the bottom of our hearts: Will you donate what you can, so we can continue providing journalism in the service of justice and truth?